You just read:

Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy

News provided by

Akcea Therapeutics, Inc.

May 14, 2020, 16:05 ET